T-Cell Vaccination ( DrugBank: - )


1 disease
IDDisease name (Link within this page)Number of trials
13Multiple sclerosis/Neuromyelitis optica2

13. Multiple sclerosis/Neuromyelitis optica


Clinical trials : 3,340 Drugs : 2,163 - (DrugBank : 383) / Drug target genes : 241 - Drug target pathways : 238
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT00228228
(ClinicalTrials.gov)
May 200226/9/2005TCV -01-002: T-Cell Vaccination in the Treatment of Probable Multiple SclerosisT-Cell Vaccination in the Treatment of Probable Multiple SclerosisMultiple SclerosisBiological: T cell vaccinationSheba Medical CenterNULLRecruiting15 Years50 YearsBoth80Phase 3Israel
2NCT00220428
(ClinicalTrials.gov)
July 199814/9/2005T-Cell Vaccination in Multiple Sclerosis (MS)The Effect of T-Cell Vaccination in Multiple Sclerosis - Phase I/II Safety and Efficacy TrialMultiple SclerosisBiological: T-Cell VaccinationSheba Medical CenterNULLRecruiting16 Years60 YearsBoth20Phase 1/Phase 2Israel